In contrast, it is still unknown how FXR affects cholesterol and lipoprotein production in clinical trials, and giving individuals with NASH an FXR agonist raises their cholesterol levels and negatively affects their lipoprotein levels [169]. Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.